Equillium Beats Q3 Estimates, Cash Runway Extended Into 2029
EQ sits 77% above its 52-week low of $0.756 on light trading volume (0.3× avg).
Summary
Equillium posted a Q3 net loss of $4.58 million, or $0.04 per share, versus consensus of $5.89 million and $0.05 — a modest beat on both lines. Operating expenses came in at $5.05 million against a $6.14 million estimate, with R&D spending rising as EQ504 moved into the clinic. The company ended the quarter with $53.3 million in cash and says that funds operations into 2029, following the $20 million milestone tranche closed in late October. The real story is EQ504: first-in-human dosing started in October, proof-of-mechanism data is expected in Q2 2027, and a proof-of-concept ulcerative colitis study is planned for H2 2027 if those results support it. At a roughly $84 million market cap, the 2029 runway removes near-term financing risk and keeps the focus on that 2027 readout.
At the time of this announcement, EQ was trading at $1.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.7M. The 52-week trading range was $0.76 to $3.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.